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Intracardiac tumors: results from a single heart center
Kalp içi tümörler: Tek kalp merkezinin sonuçları
İhsan Alur, Tevfik Güneş, Ali Vefa Özcan, İbrahim Gökşin, Gökhan Önem, Bilgin Emrecan
ÖZ
Amaç: Bu çalışmada kalp cerrahisi merkezimizde kalp içi 
tümörlerin cerrahi tedavi sonuçları sunuldu.
Ça­lış­ma­ pla­nı:­ Nisan 2006 - Mayıs 2015 tarihleri 
arasında ameliyat edilen kalp içi tümörlü 21 hastanın 
(15 erkek, 6 kadın; ort. yaş 60.9 yıl; dağılım 35-87 yıl) 
verileri retrospektif olarak incelendi. Hastalara ameliyat 
öncesi transtorasik ekokardiyografi ve bilgisayarlı 
tomografi veya manyetik rezonans görüntüleme ile tanı 
kondu.
Bul gu lar: Ortalama takip süresi 27.85 aydı. Yirmi bir 
hastanın 12’sinde benign ve dokuzunda malign tümör 
tespit edildi. Benign tümörlerin dokuzu miksoma, biri 
intramusküler lipom, biri interatriyal septal lipom ve 
biri papiller fibroelastom idi. Malign tümörlerin sekizi 
metastatik ve biri primer tümör idi. Tüm hastalarda kalbe 
ulaşmak için medyan sternotomi yapıldı. Bazı hastalarda 
cerrahi sırasında kardiyak kitle nedeniyle trombüsler tespit 
edildi.
So­nuç:­ Çalışma sonuçlarımız kalp içi trombüs ve 
tümörlerinin tanısında önemli düzeyde bir karışıklık 
olduğunu göstermektedir. Bu nedenle, başka bir neden 
tespit edilemediğinde, plevral veya perikardiyal efüzyonlu 
hastalarda metastatik kardiyak tümörler akla gelmelidir.
Anah­tar­söz­cük­ler: Kalp tümörü; metastaz; primer; cerrahi.
ABSTRACT
Background:­This study aims to present the results of surgical 
treatment of intracardiac tumors in our cardiac surgery center.
Methods: Data of 21 patients with intracardiac tumors 
(15 males, 6 females; median age 60.9 years; range 
35 to 87 years) who underwent surgery between April 
2006 and May 2015 were retrospectively analyzed. The 
patients were diagnosed preoperatively by transthoracic 
echocardiography and computed tomography or magnetic 
resonance imaging.
Results:­ The mean follow-up was 27.85 months. 
Of 21 patients, 12 had benign tumors and nine had malignant 
tumors. Of the benign tumors, nine were myxomas, one 
was an intramuscular lipoma, one was an interatrial septal 
lipoma, and one was a papillary fibroelastoma. Of the 
malignant tumors, eight were metastatic tumors and one 
was a primary tumor. Median sternotomy was performed 
in all patients to access the heart. Thrombi due to a cardiac 
mass were detected intraoperatively in some patients.
Conclusion:­Our study results suggest a high-degree of 
diagnostic confusion between intracardiac thrombi and 
tumors. Therefore, metastatic cardiac tumors should be 
considered in patients with pleural or pericardial effusion 
of no other identified cause.
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Intracardiac tumors are encountered rarely in cardiac 
surgery and are often asymptomatic with an incidence 
ranging from 0.0017% to 0.28%.[1] Of these tumors, 
75% are benign (75% of these are myxomas) and 
25% are malignant (75% of these are sarcomas). 
In addition, metastatic cardiac tumors are seen more 
frequently than primary tumors.[1] The most common 
primary cardiac tumor in adults is myxoma, whereas 
rhabdomyosarcoma is the most common tumor in 
children.[2]
Five-year life expectancy rates are about 83% for 
benign, 30% for primary malignant, and 26% for 
metastatic cardiac tumors.[3] For benign tumors, surgery 
often yields good outcomes with low recurrence 
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rates.[3] In contrast, malignant tumors have a very poor 
prognosis with a life expectancy of 7-24 months.[3] 
Herein, we present the results of surgical treatment of 
intracardiac tumors in our cardiac surgery center.
PATIENTS AND METHODS
Data of a total of 29 patients who underwent surgery 
for intracardiac tumors between April 2006 and 
May 2015 were retrospectively analyzed. Due to 
intraoperative diagnosis of thrombus, eight patients 
were excluded from the study. The study included 
21 patients (15 males and 6 females; mean age 
60.9 years; range, 35 to 87 years). Data including 
the demographic and clinical characteristics of the 
patients such as age, gender, smoking status, and 
comorbidities (hypertension, diabetes mellitus, 
peripheral artery disease, chronic obstructive 
pulmonary disease) were retrieved from the hospital 
database. Preoperative diagnosis was established 
using transthoracic echocardiography (TTE) and 
computed tomography (CT) or magnetic resonance 
imaging (MRI). Median sternotomy was performed 
in all patients during surgery. The following patient 
data were recorded: type and localization of the 
tumor, clinical signs and symptoms on admission, 
the length of postoperative stay in the intensive care 
unit and hospital, the amount of drainage and blood 
products transfused, the presence of atrial fibrillation 
(AF), mortality rate, and primary cancer diagnosis in 
cases with metastatic tumors.
The study protocol was approved by the Medical 
Faculty of Pamukkale University Ethics Committee. 
A written informed consent was obtained from each 
patient. The study was conducted in accordance with 
the principles of the Declaration of Helsinki.
RESULTS
The demographic and clinical features of the patients 
are presented in Table 1. Of 21 patients, 12 had benign 
tumors and nine had malignant tumors. Of the benign 
cases, nine were myxomas, one was an intramuscular 
lipoma, one was an interatrial septal lipoma, and one 
was a papillary fibroelastoma (PFE). Of the malignant 
cases, eight were metastatic tumors and one was a 
primary tumor (an angiosarcoma). Three patients 
had malignant epithelial tumor metastases, one had a 
lung adenocarcinoma metastasis, one had a malignant 
epithelial tumor metastasis of papillary-type renal cell 
carcinoma, one had a thymoma with thymic carcinoma, 
one had carcinoma metastasis of unknown origin, and 
one had a malignant mesenchymal tumor.
Tumor types and rates are shown in Table 2, The 
mean length of postoperative stay in intensive care unit 
and hospital, and the amount of drainage and blood 
products transfused are shown in Table 2. In patients 
with benign tumors, the most frequent symptoms on 
admission were dyspnea (52.3%) and palpitation (19%), 
while in malignant cases, the most frequent signs 
and symptoms were dyspnea (52.3%) and pericardial/
pleural effusion (23.8%).
The mean follow-up was 27.85 (range, 0 to 110) 
months. Benign and malignant cases were followed 
for a mean duration of 41 months and 10.7 months, 
respectively. Preoperative thromboembolic phenomena 
were observed in two patients (9%) diagnosed with 
myxomas. One patient (4.7%) had left hemiplegia 
with mild sequelae, while one (4.7%) had a transient 
Table 1. Demographic data and clinical characteristics 
of patients
 n %
Gender
Male 15 71.4
Female 6 28.6
Hypertension 14 66.7
Diabetes mellitus 5 23.8
Smoking 6 28.6
Chronic obstructive pulmonary disease 2 9.5
Peripheral arterial disease 1 4.8
Dyspnea 11 52.4
Palpitation 4 19
Peripheral edema 2 9.5
Cerebrovascular accident 2 9.5
Chest pain 2 9.5
Fatigue 1 4.8
Incidentally 5 23.8
Table 2. Tumor types and rates
 n %
Benign  
Myxoma 9 42.9
Intramuscular lipoma 1 4.7
Interatrial septal lipoma 1 4.7
Papillary fibroelastoma 1 4.7
Malignant  
Primary  
Angiosarcoma 1 4.7
Metastatic  
Malignant epithelial tumor 4 19
Lung adenocarcinoma 1 4.7
Carcinoma 1 4.7
Malignant mesenchymal tumor 1 4.7
Thymoma with thymic carcinoma 1 4.7
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ischemic attack. Overall, AF was found in 19% of 
patients with benign tumors and 14.2% of patients with 
malignant tumors.
The in-hospital mortality rate was 33% (n=7). Of 
these patients, two (9%) had benign tumors and five 
(23.8%) had malignant tumors. One patient with a right 
atrial lipoma had aortic stenosis and insufficiency, 
mitral valve stenosis and insufficiency, and tricuspid 
valve insufficiency. This patient also had a permanent 
complete atrioventricular (AV) block with a permanent 
right atrial pacemaker lead. Despite the attempts 
to survive through tumor excision, aortic valve 
replacement, and mitral and tricuspid annuloplasty, the 
patient died due to cardiac failure in the 21st day after 
surgery. Another patient with a benign tumor who died 
had PFE. This patient presented with chest pain caused 
by a coronary embolism. The patient died from multi-
organ and cardiac failure in the eight postoperative 
day.
The first patient with a malignant tumor had a 
primary malignant lung epithelial tumor with a left 
atrial metastasis. The patient underwent aortic valve 
replacement two years previously. The patient died 
from cardiopulmonary failure three days after surgery. 
The second patient had a malignant epithelial tumor 
with a papillary-type renal cell carcinoma as the 
primary tumor. This patient underwent nephrectomy 
and right atrial mass excision in the same session. The 
patient died in the early postoperative period due to 
renal failure and low cardiac output. The third patient 
had a malignant mesenchymal tumor with an unknown 
primary tumor. This patient died from low cardiac 
output and hepatic failure in the sixth postoperative day. 
The fourth patient had a primary malignant epithelial 
lung tumor with a left atrial metastasis. This patient 
suffered from an arrest during the anesthesia induction 
and underwent cardiopulmonary bypass surgery after 
resuscitation. Following resection, the patient died 
from low cardiac output in the early postoperative 
period. The fifth patient had an angiosarcoma. The 
tumor had transmurally enlarged the right atrium, 
invading the superior and inferior vena cava, superior 
pulmonary vein, and the free wall of the right ventricle. 
The mass in the right atrium was resected extensively 
and the defect was closed with a pericardial patch. 
This patient died from pulmonary failure 29 days 
later following surgery. After discharge, one patient 
died from a cerebrovascular disorder 11 months after 
surgery.
DISCUSSION
Myxomas are the most common benign cardiac 
tumors.[2,3] These tumors develop most commonly 
between the fourth and sixth decades of life in 
females.[4] They are most often localized in the left 
atrium (75%); however, they may also develop in 
the right atrium (15-20%) and ventricles (3-4%).[4] 
Genetically transmitted myxomas occurs in individuals 
with Carney complex, which is related to cardiac 
and cutaneous myxomas, endocrine hyperfunction 
(i.e., of the adrenals, pituitary gland, thyroid, and 
Sertoli cells), and cutaneous hyperpigmentation 
(a form of lentiginosis).[5,6] Cardiac tumors can present 
with intracardiac obstruction, as well as common 
extracardiac signs and symptoms, such as systemic 
embolization and fever, cachexia, arthralgia, Raynaud’s 
phenomenon, itching, and anemia.[1] Stroke, myocardial 
infarction, malignant arrhythmia, and related sudden 
cardiac death can be the first signs of these tumors.[2]
Taş et al.[4] reported that 67.7% of patients with 
myxomas were females and 32.3% were males, 
resulting in a female: male ratio of about 2:1. Consistent 
with these findings, in the present study, six patients 
with a myxoma were females and three were males, 
resulting in a female: male ratio of 2:1. In our study, 
the tumors were localized in the left atrium in seven 
(77.8%) patients and in the right atrium in two 
(22.2%) patients. Similarly, Taş et al.[4] reported tumor 
localizations in the left and the right atria in 93% and 
6% of their patients, respectively. The mean age was 
49.8 (range, 5 to 76) years in the aforementioned study. 
Also, Aval et al.[7] reported a mean patient age of 50.6 
(range, 13 to 76) years. Consistent with the literature 
data, the mean age was 55.6 (range, 35 to 73) years in 
our study.
Despite their benign nature, myxomas can cause 
serious symptoms, and complications due to their 
location and size.[1,4] They may cause systemic 
extracardiac signs, such as obstruction, peripheral/
cerebral embolization, prostration, weight loss, fever, 
muscle pain, joint pain, and anemia.[4,8] In their study of 
42 myxoma cases, Aval et al.[7] reported symptoms of 
Table 3. Postoperative data
 n Mean±SD
Intensive care unit mean time (hour)  23.3±13
Hospitalization mean time (day)  7.2±5.2
Mean drainage (mL)  573.8±344
Mean blood transfusion (unit)  3.2±1.5
Mean ejection fraction (%)  58±6.7
Mean PAP (mmHg)  37.8±14.1
Postoperative atrial fibrillation 7
SD: Standard deviation; PAP: Pulmonary artery pressure.
Alur et al. Intracardiac tumors: results from a single heart center
465
dyspnea in 54.8% of patients, dyspnea, and palpitation 
in 28.5%, syncope in 2.4%, and swelling in the legs in 
4.8% of patients. In this study, the presenting symptoms 
of patients with myxomas were dyspnea and palpitation 
in six (66.7%) patients, syncope in two (22.2%), and 
swelling in the legs in one (11.1%) patient. With an 
increased tumor mass, myxomas may cause dilatation 
in the left atrium and a consequent increase in left 
atrial diameter; this progression ultimately decreases 
the left atrial volume, which may cause hemodynamic 
changes in blood flow from the atrium to the ventricle 
and rhythmic disorders (AF).[4]
Treatment options for intracardiac tumors include 
simple, complex, or surgical excision; total artificial 
heart implantation; and cardiac transplantation. For 
benign tumors such as myxomas, simple resection is 
usually sufficient.[9] Pineda et al.[10] found no significant 
difference in morbidity or mortality between minimally 
invasive surgery and median sternotomy groups. 
Compared to a standard median sternotomy approach, 
minimally invasive cardiac surgical techniques have 
been shown to be advantageous for the resection of 
benign cardiac tumors. These advantages include 
reduced surgical injuries, blood loss, and pain, as 
well as more rapid return to functional activity, 
shorter intensive care unit and hospital stays, and 
a higher level of patient satisfaction.[10] The authors 
found that a minimally invasive approach with right 
mini-thoracotomy for the resection of benign cardiac 
masses might be performed safely with less resource 
utilization. In another study including 34 patients 
undergoing atrial mass removal, Russo et al.[11] reported 
similar results. With a follow-up period of 4.8 years, 
they demonstrated that a minimally invasive approach 
to cardiac mass resection was as safe and effective as 
median sternotomy.[10] In the present study, all patients 
underwent median sternotomy and cardiopulmonary 
bypass.
Aval et al.[7] reported postoperative AF in 9.5% of 
patients, partial heart block in 7.1%, paroxysmal atrial 
tachycardia with heart block in 2.3%, and complete 
heart block in 2.3% of patients. Taş et al.[4] reported 
postoperative AF in 10% of patients, temporary nodal 
rhythm in 9%, and AV block in 4% of their cases. 
In this study, we observed AF in 11.1% of patients, 
which is consistent with previous studies. Aval et al.[7] 
reported a mean follow-up of 48.8 (range, 1 to 82) 
months, and Taş et al.[4] reported a duration of 123.4 
(range, 3 to 322) months. In this study, the mean 
follow-up was 51.8 range, 6 to 110) months, which 
was similar to the results reported by Aval et al.[7] In 
addition, PFE was found in one patient. Consistent with 
the literature findings, a 76-year-old patient presented 
with chest pain caused by coronary embolization. 
These fatal complications were due to the location of 
the embolization in the left cardiac chambers, near the 
cardiac valves. Many authors believe that the cause of 
embolization is tumor coverage by fibrin fibers.[12]
The most frequently observed primary malignant 
cardiac tumor is sarcoma. Angiosarcoma is the most 
prevalent sarcoma type in adults; it affects more 
males than females (male: female ratio, 2:1), and 
develops in the right atrium in 80% of cases.[13] As the 
tumor spreads via a hematogenous route, metastases 
occur rapidly and frequently, and are widespread. 
These tumors may metastasize in the superior and 
inferior vena cava, tricuspid valve, right ventricular 
free wall, ventricular septum, and even in the right 
coronary artery.[13] Early diagnosis of the tumor may 
be challenging, as it may cause chest pain, respiratory 
distress, and nonspecific extracardiac symptoms.[2] At 
the time of diagnosis, lung, liver, and brain metastases 
are present in 4 to 89% of cases.[5] In this study, the 
patient with an angiosarcoma had also the right atrium 
and vena cava involvement.
In the majority of cases, mortality is due to distant 
organ metastases.[6] Metastatic cardiac tumors are 100 
times more frequent than primary cardiac tumors 
with an incidence of 10%.[6] Cardiac invasion by 
metastatic tumors occurs via four different routes: the 
direct route by mediastinal tumors and hematogenous, 
intracavitary (i.e., via inferior and superior vena 
cava), and lymphatic routes.[14] The lymphatic route 
is the most frequent route for secondary cardiac 
involvement. Malignant melanomas and thymomas 
are the tumors having the highest potential for 
cardiac metastases.[13,15] Melanomas have a high rate 
of cardiac metastasis (about 50%). About 30% of 
patients with metastatic cardiac tumors have congestive 
cardiac insufficiency, tachyarrhythmia, or isolated 
cardiomegaly symptoms. In these patients, pericardial 
effusion and, subsequently, cardiac tamponade may 
develop due to the presence of multiple lesions of 
metastatic invasion in the mediastinal lymph nodes. 
Despite the absence of symptoms, emerging pericardial 
effusion and cardiac tamponade indicate malignant 
cardiac involvement in 90% of cases.[13] Therefore, 
metastatic cardiac tumors and, subsequently, secondary 
cardiac involvement should be considered in patients 
with cancer who present with tachyarrhythmia, 
isolated cardiomegaly, symptoms of congestive cardiac 
insufficiency, new pericardial effusion, and cardiac 
tamponade. For patients with malignant tumors treated 
with conservative chemotherapy and radiotherapy, the 
Turk Gogus Kalp Dama
466
mean life expectancy is less than one year. Simple or 
incomplete resection prolongs the survival for only 
a few months in patients with malignancy.[3] Radical 
resection and, if necessary, chemotherapy can improve 
long-term results and patients’ quality of life.[9]
In our series, the number of metastatic malignant 
tumors (38%) was higher than that of malignant 
primary tumors (4.7%). With regard to the localization 
of the tumor, 44% were localized in the left atrium, 44% 
in the right atrium, and 12% in the left ventricle. Three 
patients had malignant epithelial tumor metastases, 
one had a lung adenocarcinoma metastasis, one had a 
malignant epithelial tumor metastasis of papillary-type 
renal cell carcinoma, one had a thymoma with thymic 
carcinoma, one had carcinoma metastasis of unknown 
origin, and one had a malignant mesenchymal tumor.
Dias et al.[1] reported that 72% of their patients were 
asymptomatic on presentation to the hospital, whereas 
10.9% showed systemic manifestations, such as fever 
(4.8%), chronic anemia (4%), weight loss (1.6%), and 
arthralgia (0.5%). In this study, our patients’ complaints 
on presentation were dyspnea (52.3%), palpitation 
(19%), swelling in the legs (9.5%), cerebrovascular 
accidents (9.5%), chest pain (9.5%), and malaise (4.7%), 
and 23.8% of patients were diagnosed incidentally.
Vegetation, thrombus, and tumor should be 
considered in the differential diagnosis of an intracardiac 
mass. Dias et al.[1] reported that a tumor mass might be 
confused with a thrombus, as a thrombus could mimic 
a tumor in 6.4% of patients and that the differential 
diagnosis was possible intraoperatively. Another study 
documented thrombi in 15.4% of patients operated 
for cardiac tumors.[16] In this study, thrombi were 
found intraoperatively or through histopathological 
examination in eight (27.6%) patients who underwent 
surgery for cardiac tumors. On contrast, the rate at 
which thrombi were found in this study is higher than 
those reported in the aforementioned studies. One 
possible reason is that the study group was smaller than 
the groups examined by Dias et al.[1] and Strecker et 
al.,[16] who included 323 patients with primary cardiac 
tumors and reported data from a 48-year follow-up 
period. In addition, Elbardissi et al.[17] reported that the 
prognosis for malignant tumors was worse than that 
for benign tumors and that the mean survival time was 
less than one year, despite resection and aggressive 
adjuvant chemotherapy. Currently, the mortality and 
morbidity rates have been decreasing steadily in 
patients with cardiac tumors thanks to the developments 
in diagnostic methods and the more frequent use of CT 
and MRI in the differential diagnosis of intracardiac 
masses, resulting in a more accurate early diagnosis 
and surgical planning. Dias et al.[1] reported that 
the mortality rate for an intracardiac tumor surgery 
improved from 16% in 1980-1998 to 6% by 2004 and 
5.4% in 2014, the last year included in that publication. 
In this study, the mortality rate was 33.3%. This high 
rate is likely due the inclusion of a large number (38%) 
of patients with advanced metastatic tumors.
On the other hand, this retrospective study has 
several limitations. The major limitation of the study 
was its small sample size. Another limitation was 
the relatively high-mortality rates, as the sample 
included more cases of metastatic malignant tumors 
than malignant primary tumors.
In conclusion, metastatic cardiac tumors and 
associated secondary cardiac involvement should be 
considered in the diagnosis of patients with cancer who 
present with tachyarrhythmia, isolated cardiomegaly, 
symptoms of congestive cardiac insufficiency, 
emerging pericardial effusion, or cardiac tamponade. 
Thrombi are also seen in some patients undergoing 
operations for cardiac masses, suggesting a high 
degree of diagnostic confusion between intracardiac 
thrombi and tumors.
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